Find Emapticap pegol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Emapticap pegol, Olaptesed pegol, Nox-a12 free acid, Nox-e36 free acid, Emapticap pegol [inn], Olaptesed pegol [inn]
Molecular Formula
C18H37N2O10P
Molecular Weight
472.5  g/mol
InChI Key
QJAGBAPUFWBVSD-UHFFFAOYSA-N

Emapticap pegol
Olaptesed Pegol is a 45-mer L-stereoisomer RNA oligonucleotide linked to a 40 kDa polyethyleneglycol that targets the small chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) with potential antineoplastic and hematopoietic stem cell-mobilization activities. SDF-1 targeted agent NOX-A12 specifically binds to SDF-1 thereby preventing the binding of SDF-1 to its receptors CXCR4 and CXCR7 blocking the subsequent receptor activation. This may prevent angiogenesis, tumor cell proliferation, invasion and metastasis and could sensitize tumor cells to chemotherapy. In addition, inhibition of SDF-1/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into blood. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and does not hybridize with native nucleic acids. Furthermore, this agent does not induce the innate immune response and has shown a favorable immunogenicity profile.
1 2D Structure

Emapticap pegol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-[[2-[[2-(2-methoxyethoxy)acetyl]-[2-(2-methoxyethoxy)ethyl]amino]acetyl]amino]hexyl dihydrogen phosphate
2.1.2 InChI
InChI=1S/C18H37N2O10P/c1-26-11-13-28-10-8-20(18(22)16-29-14-12-27-2)15-17(21)19-7-5-3-4-6-9-30-31(23,24)25/h3-16H2,1-2H3,(H,19,21)(H2,23,24,25)
2.1.3 InChI Key
QJAGBAPUFWBVSD-UHFFFAOYSA-N
2.1.4 Canonical SMILES
COCCOCCN(CC(=O)NCCCCCCOP(=O)(O)O)C(=O)COCCOC
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Nox-h94

2.2.2 Depositor-Supplied Synonyms

1. Emapticap Pegol

2. Olaptesed Pegol

3. Nox-a12 Free Acid

4. Nox-e36 Free Acid

5. Emapticap Pegol [inn]

6. Olaptesed Pegol [inn]

7. Lexaptepid Pegol [inn]

8. Unii-7x623i7ciy

9. Unii-ctl75x0v60

10. Unii-mtm792b442

11. 7x623i7ciy

12. Ctl75x0v60

13. Mtm792b442

14. 1390628-22-4

15. 1390630-22-4

16. 1390631-57-8

2.3 Create Date
2014-11-22
3 Chemical and Physical Properties
Molecular Weight 472.5 g/mol
Molecular Formula C18H37N2O10P
XLogP3-1.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count21
Exact Mass472.21858238 g/mol
Monoisotopic Mass472.21858238 g/mol
Topological Polar Surface Area153 Ų
Heavy Atom Count31
Formal Charge0
Complexity518
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty